GSK-F1

GSK-F1 (Compound F1) is an orally active PI4KA inhibitor with pIC50 values of 8.0, 5.9, 5.8, 5.9, 5.9 and 6.4 against PI4KA, PI4KB, PI3KA, PI3KB, PI3KG and PI3KD, respectively. GSK-F1 can be used for HCV infection research[1].

Product Specifications

CAS Number

[1402345-92-9]

UNSPSC

12352005

Target

PI3K; PI4K

Type

Reference compound

Related Pathways

PI3K/Akt/mTOR

Applications

COVID-19-immunoregulation

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/gsk-f1.html

Purity

95.06

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

O=S(C1=CC(C2=CC3=C(N=C(N)N(C4=CC=CC=C4C(F)(F)F)C3=O)C=C2)=CN=C1OC)(NC5=CC=C(F)C=C5F)=O

Molecular Formula

C27H18F5N5O4S

Molecular Weight

603.52

References & Citations

[1]Bojjireddy N, et al. Pharmacological and genetic targeting of the PI4KA enzyme reveals its important role in maintaining plasma membrane phosphatidylinositol 4-phosphate and phosphatidylinositol 4,5-bisphosphate levels. J Biol Chem. 2014 Feb 28;289 (9) :6120-32.